Wednesday, May 14, 2025
8:00 am Check-In Light Breakfast & Morning Networking
8:50 am Chair’s Opening Remarks
Decoding IBD Heterogeneity with Better Diagnosis for Enhanced Patient Subtyping to Improve Patient Safety & Response Rate in Clinical Trials
9:00 am Leveraging Multi-Omics to Uncover Deeper Insights into IBD Heterogeneity for Improved Patient Subtyping
Synopsis
- How to integrate transcriptomics across diverse cohorts for granular patient subtyping
- Identifying novel markers linked to inflammation signatures to enhance clinical trial outcomes
- How to bridge gaps between phenotypic data and actionable therapeutic strategies in IBD
9:30 am Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate Response Rate for Therapeutics in IBD
Synopsis
- Sharing insights from the integration of a diagnostic tool in a phase II trial, highlighting successes, challenges, and learnings from its development
- Discussing the role of patient stratification in advancing therapeutic precision and optimizing treatment pathways for IBD
- Exploring the future potential of diagnostic innovations in clinical trials and their role in shaping precision medicine strategies
10:00 am Morning Speed Networking Break
Synopsis
As the Precision Medicine and IBD community come together, this valuable session offers the perfect opportunity to connect with peers and build meaningful relationships. Attendees will have the chance to meet, network, and collaborate with industry leaders driving innovation in IBD care.
Harnessing Prognostic Biomarkers & Monitoring Tools to Enable Personalized Treatment Plans & Revolutionize Therapeutic Efficacy
11:00 am Individual Response Trajectories in IBD Defines Patent Clusters for Precision Medicine
Synopsis
- Large level of individual heterogeneity in patients with IBD including therapy responses
- Response dynamics cluster patients into new subpopulations
- Difference in clinical therapy response are underlaid by biomarker profiles
11:30 am Roundtable Discussion: Advancing Disease Prediction through the Development & Validation of Prognostic Biomarkers for Personalized IBD Treatments
Synopsis
- What is the clinical utility of biomarkers in predicting disease course?
- Can biopharma identify immune profiles linked to patient outcomes in early IBD stages?
- How can we accelerate the validation of biomarkers to enhance treatment efficacy?
12:30 pm Lunch Break & Networking
Advancing Precision Therapies with Nanomedicine & Microbiome Innovations to Unlock Novel Opportunities for Patients with IBD
1:30 pm Therapeutic Application of NavacimTM, a Precision Nanomedicine Platform, in IBD
Synopsis
- History of type-1 regulatory T cells and navacim in ameliorating inflammatory diseases
- Nonclinical safety and pharmacology studies supporting the use of navacims in first-in-human studies
- Clinical translational and proof-of-concept studies
2:00 pm Harnessing the Microbiome to Advance Precision Medicine & Transform Therapeutics for IBD
Synopsis
- How can biopharma leverage microbiome-targeted treatments to reduce inflammation?
- Using biomarkers to stratify populations for microbiome-targeted therapeutics
- Advancing therapeutic development using microbiome-modifying strategies
- Leveraging microbiome signatures to enhance patient response to therapies
2:30 pm A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells
Synopsis
- Antagonists to retinoic acid receptor-alpha (RARα) block upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes
- Inflammatory damage to mucosal epithelia is significantly inhibited in colitis and related disease models by concomitant daily oral dosing of an RARα antagonist
- Preclinical safety findings for the highly selective RARα antagonist OR-812 support further development
3:00 pm Afternoon Networking Break
Transforming IBD Treatment with Optimized Combination Therapies & Emerging Precision Modalities to Offer More Efficacious Therapeutics
3:30 pm Panel Discussion: Future Horizons in Precision Medicine: Exploring New Modalities & Technologies for IBD
Synopsis
- Discussing emerging therapeutic modalities and their potential to reshape IBD treatment strategies
- Identifying critical challenges and opportunities in developing precision medicine approaches
- Envisioning the integration of novel technologies to improve patient outcomes and drive innovation
- How will combination therapies shape the future of treatments for IBD?
4:30 pm Advancing Combination Therapies to Change the Treatment Paradigm in IBD
Synopsis
- Scientific and clinical rationale for targeting ɑ4β7, TL1A, and IL-23 pathways in IBD therapy
- Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments
- Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directions